However, the high density and selective expression of CD48 on hematopoietic cells still make it a strong candidate for an avidity-based approach, where enhanced CAR T-cell “locking on” could be leveraged to promote more effective targeting of MM cells. This evidence concerns the gene CD48 and Miyoshi myopathy.